EGFR-targeted antisense oligonucleotides modified with boron clusters offer an innovative approach to cancer chemo-radiotherapy
Damian Kaniowski, Katarzyna Ebenryter‐Olbińska, Justyna Suwara, Katarzyna Kulik, Jeremy Hall, Dongfang Wang, Elaine Y. Kang, Rafał Dolot, Alessandro Somenzi, Agata Jakóbik‐Kolon, Nicoletta Protti, Saverio Altieri, Marcin Kortylewski, Barbara Nawrot
This paper demonstrates that B-ASOLNA-CHOL, a boron cluster-conjugated antisense oligonucleotide, enhances cancer cell uptake and cytotoxicity when combined with radiotherapy, reducing tumor size in xenograft models.
bioRxiv · Aug 7, 2025 · PreprintBiochemistry